<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572324</url>
  </required_header>
  <id_info>
    <org_study_id>PUCH12031308</org_study_id>
    <nct_id>NCT01572324</nct_id>
  </id_info>
  <brief_title>Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas</brief_title>
  <official_title>Phase II Study of Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil in Patients With Unresectable Biliary Tract Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic
      arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary
      tract carcinomas, and to explore a better first-line treatment regimen for these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rates</measure>
    <time_frame>4 months</time_frame>
    <description>Describe the overall response rate with a 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survivial</measure>
    <time_frame>2 years</time_frame>
    <description>Describe median PFS with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of HAI</measure>
    <time_frame>1 months</time_frame>
    <description>Toxicity as measured by NCI Common Toxicity Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Describe median overall survival with a 95% confidence interval and estimate the overall survival rate at 12 and 24 months with 24 months with a 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Arterial infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine</intervention_name>
    <description>HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.</description>
    <arm_group_label>Arterial infusion</arm_group_label>
    <other_name>1-OHP, Dacotin, Eloxatin, L-OHP;</other_name>
    <other_name>5-Fluorouracil,5FU;</other_name>
    <other_name>Levofolinic acid,Folinic acid.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have histologically or cytologically confirmed Biliary tract carcinomas
             including intrahepatic, hilar cholangiocarcinoma and gallbladder cancer without
             evident liver metastasis.

          -  Patient must have locally advanced disease that is unresectable after review by the
             Hepatobiliary Surgery service

          -  Patient's Eastern Cooperative Oncology Group (ECOG) performance status must be =&lt; 2
             (Karnofsky &gt;= 60%)

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin &gt;= 90g/L

          -  Total bilirubin =&lt; 2 X institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
             =&lt; 2.5 X institutional upper limit of normality

          -  Creatinine =&lt; 1.5 X institutional upper limit of normal

          -  Albumin &gt;= 30g/L

          -  Patient must be able to understand and willing to sign a written informed consent
             document

        Exclusion Criteria:

          -  Patients who have had prior chemotherapy and other antitumor therapy treatment

          -  Patient who is receiving any other investigational agents

          -  Patient who have evident distant (M) disease;

          -  Patient who have a diagnosis of hepatic encephalopathy

          -  Patients who have a diagnosis of sclerosing cholangitis.

          -  Patients who have a diagnosis of Gilbert's disease.

          -  Patients who have clinical ascites

          -  Patient must not have any uncontrolled concurrent illness including, but not limited
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus and hypertension, or
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  No other malignancy except localized basal cell or squamous cell skin cancer in the
             past 5 years

          -  Patient who is pregnant or lactating

          -  Patient Allergic to Iodine contrast medium

          -  Uncontrolled severe coagulation disorders (INR &lt; 1.5 in patients not on warfarin
             therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaodong Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer hospital &amp; Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>January 2, 2017</last_update_submitted>
  <last_update_submitted_qc>January 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xiaodong Wang, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>gallbladder cancer</keyword>
  <keyword>Infusions</keyword>
  <keyword>Intra-Arterial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

